Skip to main content

Oral GLP-1 analogue: perspectives and impact on atherosclerosis in type 2 diabetic patients


Cardiovascular events related to atherosclerosis are responsible for high morbidity and mortality among patients with type 2 diabetes. Improvement in care, especially in early stages, is crucial. Oral semaglutide, a glucagon-like peptide 1 analogue, controls blood glucose and results in significant body weight loss in patients with type 2 diabetes. Beyond these well-known effects, an interesting aspect of this drug is its antiatherogenic activity, which should be further explored in clinical practice. This paper reviews the evidence related to oral semaglutide decreasing cardiovascular risk in patients with type 2 diabetes, focusing on the drug’s antiatherosclerotic properties. The glucagon-like peptide 1 analogue restores endothelial dysfunction, induces vasodilatation, and reduces plasma lipids. Oral semaglutide showed cardiovascular safety profile, with significant reduced risk of death from cardiovascular events. Based on current data, clinicians should consider oral semaglutide for type 2 diabetes management.


Type 2 diabetes mellitus (T2DM) is a prevalent disease with the potential to become a pandemic and one of the leading causes of mortality worldwide [1, 2]. More than 400 million people worldwide have T2DM [3], and its incidence increases as the population ages, obesity increases, and urbanization progresses [4,5,6,7].

The most prevalent cardiovascular complication of T2DM is related to atherosclerosis and its complications, such as acute myocardial infarction, stroke, and peripheral artery disease, which are responsible for high mortality and morbidity among T2DM patients. In a recent large cross-sectional study evaluating 9823 T2DM patients from around the world (including Brazil), 34.8% of patients had established cardiovascular disease (CVD), of whom 85.8% had atherosclerotic cardiovascular disease (ASCVD) [8]. Among the 43.9% of the study population composed of Brazilian patients (n = 912), 85.8% had ASCVD [9]. The prevalence of coronary heart disease (CHD) was 27.9%; 8.7% presented cerebrovascular disease, and 3.4% presented carotid artery disease [9]. ASCVD quadruples the risk of CHD, doubles the risk of stroke, and triples the risk of death [10]. T2DM generates an environment prone to atherogenesis. Chronic hyperglycaemia, the production of reactive oxygen species (ROS), and the release of inflammatory cytokines are some of the factors causing endothelial dysfunction in patients with diabetes [11, 12]. This endothelial dysfunction decreases the potent vasodilator nitric oxide (NO) in endothelial and vascular muscle smooth cells, increases the levels of vasoconstrictors such as endothelin-1 [13], and creates a hypercoagulable state by activating platelet aggregation and inhibiting fibrinolysis [14]. Compared to individuals without diabetes, patients with diabetes present a higher atheroma volume, a smaller arterial lumen, more rapid progression of atherosclerosis, more macrophage accumulation, and a higher incidence of thrombus [15, 16]. A study examining coronary atherectomy specimens showed that 62% of patients with T2DM presented coronary thrombus compared with 40% of patients without diabetes (p = 0.04) [16].

Since the discovery of insulin, the main goal of diabetes treatment has been the control of glycaemia to prevent complications. Despite the benefits observed in adequate glycemic control in reducing microvascular events the results are controversial in regard to atherosclerotic disease [17]. Therefore, advances in T2DM therapies are crucial, especially in the early stages of the disease; treatment must effectively decrease the risk before atherosclerosis is established.

Questions regarding the cardiovascular safety of drugs prescribed for T2DM arose as individuals treated with sulfonylureas and insulin showed an increased incidence of major adverse cardiovascular events (MACEs: death from cardiovascular causes, nonfatal myocardial infarction, or nonfatal stroke) [18, 19]. The withdrawal of approval of rosiglitazone due to the increased risk of cardiovascular events [20] resulted in a demand for studies demonstrating cardiovascular safety for any new antidiabetic drug. Consequently, a new era of studies assessing cardiovascular outcomes began showing that some drugs are not only safe but also decrease the incidence of CVD [21, 22].

Glucagon-like peptide 1 (GLP-1) is an incretin 30 amino-acid peptide hormone produced in hindbrain neurons and in specialized enteroendocrine cells (L cells) in the distal small and large intestines that is released after food intake [23, 24]. Glucagon-like peptide 1 receptor (GLP-1R) is present not only in the central nervous system and gastrointestinal tract but also in the pancreas, kidney, lungs, cardiomyocytes, vascular smooth muscle cells, and endothelium [25,26,27,28,29]. GLP-1 acts on pancreatic cells by inhibiting the alpha cells responsible for glucagon secretion [30] and stimulating insulin production in beta cells in response to elevated blood glucose levels [23]. This combined mechanism of action of GLP-1 makes GLP-1 attractive for the treatment of T2DM.

GLP-1 analogues

GLP-1 analogues were first approved for the treatment of T2DM in 2005. Peptide drugs are highly specific, with less toxicity and fewer drug interactions. However, only the injectable form has been available because peptide drugs are usually not suitable for administration via the oral route, as they present low oral bioavailability, are inactivated when they reach the gastrointestinal tract, and have low rates of diffusion into the cell [31, 32].

Recently, the first orally administered GLP-1 analogue was approved for the treatment of T2DM. The permeation enhancer sodium N-[8-(2-hydroxybenzoyl)amino] caprylate (SNAC) co-formulated with semaglutide prevents enzyme degradation, increases its absorption in the stomach, and results in suitable bioavailability [33, 34]. The Peptide Innovation for Early Diabetes Treatment (PIONEER) programme consisted of eight phase 3, randomized, controlled clinical studies and showed that oral semaglutide reduces glycated haemoglobin (HbA1c) and body weight in patients with T2DM and has potential cardiovascular benefits [35,36,37,38,39,40,41,42].

Semaglutide and clinical atherosclerotic cardiovascular event data

Regulatory authorities recognized that GLP-1 analogues reduce the incidence of MACEs in T2DM patients, but this is only the case for GLP-1R agonists with a molecular structure based on endogenous GLP-1 (semaglutide, liraglutide, albiglutide, and dulaglutide), as they are able to reduce the relative risk of MACEs by up to 10% [43]. International guidelines recommend the use of GLP-1 analogues in T2DM patients with ASCVD or who have high cardiovascular risk [44, 45]. Moreover, considering the CVD continuum where it progresses from risk factors such as diabetes to atherosclerosis and CHD, until it leads to heart failure or death [46], GLP-1 analogues act in different stages of this pathophysiological process (see Fig. 1) without increasing the incidence of arrhythmia or hospitalization or worsening heart failure [22, 40, 47,48,49,50,51,52,53,54].

Fig. 1
figure 1

Adapted from [46]

Cardiovascular disease continuum-GLP-1 action.

Cardiovascular clinical data with oral semaglutide

Data from cardiovascular events including death were collected during the PIONEER program. A summary of all the CV events occurring during these trials are presented in Additional file 1: Table S1. In addition, a cardiovascular outcome trial (CVOT) was also specifically carried out, the PIONEER 6, to evaluate cardiovascular events in a larger population using oral semaglutide [40].

The PIONEER 6 study included 3183 T2DM patients who had ASCVD or who were at high risk, of whom 1591 were treated with oral semaglutide and 1592 were treated with placebo for a median time of 15.9 months [40]. This study was designed to evaluate the cardiovascular safety of oral semaglutide, and the results confirmed the safety, showing the noninferiority of oral semaglutide over placebo in regard to the timing of the first MACE. Nonfatal myocardial infarction occurred in 2.3% of patients treated with oral semaglutide and 1.9% treated with placebo (HR 1.18, 95% CI 0.73–1.90), nonfatal stroke occurred in 0.8% versus 1.0% treated with placebo (HR 0.74, 95% CI 0.35–1.57), and death from cardiovascular causes occurred in 0.9% versus 1.9% treated with placebo (HR 0.51, 95% CI 0.31–0.84). Long-term data are needed to confirm the cardiovascular benefits of oral semaglutide. The Heart Disease Study of Semaglutide in Patients with Type 2 Diabetes (SOUL) is a more extensive and extended phase 3 CVOT presently being conducted, and results are expected in 2024 [55]. It is a double-blind, placebo-controlled study (n = 9642 T2DM patients), assessing the use of oral semaglutide once a day (up to 14 mg) during 3.5–5 years, evaluating the cardiovascular benefit of oral semaglutide [55].

According to a meta-analysis evaluating 453 trials and 21 antidiabetic treatments, oral semaglutide reduces all-cause mortality and cardiovascular death, with the lowest odds ratios (ORs) among the treatments evaluated (empagliflozin, liraglutide, extended-release exenatide, dapagliflozin, dulaglutide, lixisenatide, canagliflozin, pioglitazone, DPP-4 inhibitors, subcutaneous semaglutide, sulphonylureas) [56]. Patients were being treated with metformin-based background therapy and were considered at high risk for a cardiovascular event [56]. The ORs for mortality in patients at high and low cardiovascular risk were 0.50 (95% Cl 0.31–0.83) and 0.58 (95% Cl 0.23–1.48), respectively [56].

Cardiovascular clinical data with subcutaneous semaglutide

The subcutaneous (sc) presentation of semaglutide decreases the risk of MACEs in patients with diabetes. Subjects from the SUSTAIN 6 study treated with sc semaglutide had a 26% reduced risk of a cardiovascular events compared with the risk among individuals who received a placebo [57]. The protective effect was more notable for nonfatal stroke, with a 39% relative risk reduction. Nonfatal stroke occurred in 1.6% of patients treated with semaglutide and 2.7% treated with placebo (hazard ratio (HR) 0.61, 95% confidence interval (CI) 0.38–0.99, p = 0.04).

Cardiovascular clinical data with pooled data from PIONEER 6 and SUSTAIN 6

Sc and oral formulations of semaglutide have been studied in a series of clinical trials in the SUSTAIN and PIONEER programs, respectively. However, there are no head-to-head studies comparing the two formulations. In a propensity score matching study, there was considerable overlap between the doses of oral semaglutide 7 and 14 mg and sc semaglutide 0.5 and 1.0 mg, respectively [58]. Population pharmacokinetic analysis indicated dose-proportional pharmacokinetic profiles for both oral and sc, with body weight being the main factor influencing exposure [58]. Similar exposure–response relationships were observed for efficacy (HbA1c and body weight) and tolerability (nausea and vomiting) of semaglutide, regardless of the route of administration [58]. A meta-analysis showed no statistically significant difference in efficacy between the two formulations at week 26, despite the numerically higher HbA1c response and body weight with sc semaglutide [59, 60].

A post hoc meta-analysis used a predictive model to evaluate the cardiovascular risk of patients from all PIONEER and SUSTAIN clinical trials (n = 18 studies) [61]. This analysis showed that semaglutide (both oral and sc) reduces the continuum relative and the absolute risk of MACE, especially in medium to high-risk patients, with no difference between trials evaluating only blood glucose control or cardiovascular events, and also with studies without active comparator, only versus placebo.

The post hoc analysis of patients only from the PIONEER 6 (evaluating oral semaglutide) and SUSTAIN 6 (evaluating sc semaglutide) studies found a 23.8% reduction in MACEs associated with semaglutide treatment (HR 0.76, 95% CI 0.62–0.92), especially in the prevention of nonfatal stroke (HR 0.65, 95% CI 0.43–0.97) [62].

Nonfatal stroke is a leading cause of disability worldwide, with high costs of medical care and a major impact on patients’ quality of life [63]. Stroke in patients with T2DM is associated with poor prognosis, high mortality, high incidence of neuromotor and neuropsychiatric sequelae, and high recurrence risk [64]. In addition to the lower incidence of nonfatal stroke in clinical trials [22, 40, 57], treatment with liraglutide or semaglutide (sc or oral) decreased the risk of dementia by 53% compared to the risk associated with placebo (HR 0.47, 95% CI 0.25–0.86) according to a pooled post hoc analysis of the LEADER, SUSTAIN 6 and PIONEER 6 trials, including 15,820 patients with T2DM [65].

Moreover, sc semaglutide showed neuroprotective activity in a stroke animal model, improved motor control and muscle strength, and reduced infarct volume, loss of neurons, and inflammation [66]. The mechanism is still unknown; experimental studies with other GLP-1 analogues (exendin-4 and liraglutide) have shown evidence of inhibition of oxidative stress, decreased apoptosis and prevalence of injured cells, decreased vascular proliferation, and increased cAMP levels in neurons and anti-inflammatory activity in microglial cells [67].

Cardiovascular clinical data with oral semaglutide versus others GLP-1 receptor agonists

Seven different GLP-1 receptor agonists have CVOTs results (see Table 1). Three of them already have a cardiovascular indication approved. Oral semaglutide shows no significant difference compared with other GLP-1 receptor agonists in the incidence of MACE, in hospitalization for heart failure, and no difference on cardiovascular death (except for Lixisenatide: HR 0.5; CI 95% 0.26–0.96) [68].

Table 1 GLP-1 receptor agonists: cardiovascular indications and CVOTs results

Anti-atherogenic mechanisms of semaglutide

Studies to elucidate the cardiovascular protection mechanisms of GLP-1 have been conducted over the years, but they are not completely understood. Human recombinant GLP-1 and analogues have direct and indirect effects that are correlated with antiatherogenic properties, acting on signalling pathways in vascular smooth muscle cells [69]. GLP-1 reduces intracellular ROS, prevents oxidative stress injury, and increases cellular protection in arterial endothelial and smooth muscle cells [70, 71]. It promotes arterial vasodilation by binding GLP-1R in endothelial cells and releasing NO [69]. GLP-1 reduces endoplasmic reticulum stress and apoptosis induced by hyperglycaemia and regulates mitochondrial function via stimulation of optic atrophy protein 1 [69]. It improves endothelial function and promotes arterial vasodilatation in T2DM patients with ASCVD [29, 72].

GLP-1 inhibits macrophage foam cell formation, preventing the development of atherosclerotic plaques [73]. SC semaglutide significantly attenuates aortic plaque lesions in nondiabetic low-density-lipoprotein-receptor-deficient mice in a dose-independent manner and affects genes related to atherosclerosis [50]. It also reduces proatherogenic inflammation, decreasing plasma levels of the inflammatory cytokines TNF-α and IFN-γ and immune cell recruitment [50]. Data from the PIONEER programme show a clinically meaningful reduction in systemic inflammation with oral semaglutide, measured by C-reactive protein [35, 36]. Visceral fat accumulation is also frequent in T2DM patients and increases atherosclerosis and cardiometabolic risk [74]. SC semaglutide reduces the epicardial adipose tissue of patients with T2DM and obesity by 20% after 12 weeks of treatment [75].

Lipids play a significant role in atherosclerotic plaque formation. GLP-1 inhibits the postprandial increase in triglycerides (TGs) and free fatty acids in patients with diabetes [76]. Treatment with oral semaglutide improves the fasting lipid level profile, as exploratory analysis resulted in a statistically superior reduction in total cholesterol [35, 38, 42], low-density lipoprotein (LDL) [35, 42], triacylglycerols (TAGs) [35, 38, 39], and very-low-density lipoprotein (VLDL) compared to the effects of placebo [38]. Compared with active drugs, oral semaglutide was superior to empagliflozin in reducing total cholesterol and LDL [36] and was superior to sitagliptin in reducing total cholesterol, LDL, and TAGs [37, 41], but there was no significant difference when compared with another GLP-1 analogue (liraglutide) [38]. Studies in mice and humans showed that GLP-1 liraglutide acts directly and indirectly in LDL and VLDL catabolism, increases lipoprotein lipase gene expression responsible for TAG hydrolysis, and reduces apolipoprotein B48, diacylglycerol O-acyltransferase 1, and microsomal transfer protein gene expression, all of which are involved in chylomicron synthesis [77, 78]. Liraglutide reduces proprotein convertase subtilisin/kexin type 9, which interferes with LDL clearance, and retinol-binding protein 4, which is related to insulin resistance [77, 78]. It also suppresses oxidized LDL action by restoring the expression of Kruppel-like transcription factor 2, an important regulator of endothelial function, by improving endothelial hyperpermeability and by reducing vascular adhesion molecule expression [79].

Moreover, oral semaglutide improves systolic blood pressure, with superior reduction compared with placebo and sitagliptin [35, 37, 40, 42], adding an extra contribution to reduce cardiovascular risk.

Blood glucose levels and atherosclerosis

One of the main strategies to reduce ASCVD risk in T2DM patients is to achieve blood glucose level control [44, 45]. Oral semaglutide showed superiority over placebo [35], empagliflozin [36], and sitagliptin [37] and noninferiority over liraglutide [38] in reducing HbA1c levels in T2DM patients. However, as noted previously by Zweck et al. [80], the normalization of HbA1c induced by oral semaglutide is directly associated with the reduction in cardiovascular risk, but it may not be related simply to improvement in glycaemic control; it may reflect drug class–mediated activation of other cardiovascular protective mechanisms. In fact, their analyses indicate that the cardiovascular efficacy of albiglutide is not driven by glycated haemoglobin [80]. An ongoing phase 3 trial, the SELECT study, will evaluate the cardiovascular benefit of semaglutide beyond blood glucose control, as the study population is composed of individuals who are overweight or obese without diabetes [81].

Oral semaglutide is associated with a low risk of hypoglycaemia because it stimulates insulin secretion according to glucose plasma levels, making this drug suitable for elderly individuals [82]. In the PIONEER programme [35,36,37,38,39,40,41,42], the most frequent adverse events were nausea and diarrhoea, which are common side effects of GLP-1 analogues. There were few hypoglycaemic events and were generally associated with sulfonylureas and insulin background therapy [35,36,37,38,39,40,41,42].

Body weight and atherosclerosis

Obesity is a significant risk factor for T2DM and an independent risk factor for ASCVD [45]. Approximately 90% of T2DM patients are overweight or obese [83]. Obesity increases inflammation and endothelial dysfunction and is associated with hypertension, dyslipidaemia, and glucose intolerance [84, 85]. Subclinical coronary atherosclerosis is strongly associated with obesity [86].

Body weight reduction decreases cardiovascular risks and can result in remission of T2DM [87]. Significant weight loss (at least 10% of body weight) reduces HbA1c, blood pressure, lipid levels [88], and the incidence of MACEs including cardiovascular death, nonfatal myocardial infarction, nonfatal stroke, and hospitalized angina by up to 21% in T2DM patients; moreover, significant weight loss reduces the requirement for procedures, such as coronary artery bypass grafting, carotid endarterectomy, and percutaneous coronary intervention, as well as peripheral vascular disease, and total mortality by up to 24% [89, 90]. Even minimal weight loss (1 kg) decreases the risk of heart failure in T2DM patients by 5.9% [90].

Patients treated with oral semaglutide experienced clinically significant weight loss, as well as a reduction in body mass index and waist circumference [35,36,37,38,39,40]. Waist circumference is a reliable indicator of abdominal obesity, and it is considered a risk factor for ASCVD independent of body mass index [91]. Treatment with oral semaglutide reduced mean body weight within the first 14 weeks of treatment, and weight loss was generally maintained throughout the trials. Oral semaglutide was superior to placebo, sitagliptin, and liraglutide and similar to empagliflozin, with losses up to 4.44 kg compared with 0.5–3.6 kg for active-comparator arms and 0.4–1.4 kg compared with placebo [35,36,37,38,39,40]. When considering study drug discontinuation or use of rescue medication (trial product estimand results), the weight loss resulting from the use of oral semaglutide was up to − 5 kg, while that associated with other active comparators ranged from − 0.8 to − 3.8 kg, and that associated with placebo ranged from − 0.1 to + 0.6 kg [35,36,37,38,39,40]. Oral semaglutide significantly decreases craving for food more than empagliflozin [36, 37], and weight loss improves patients’ quality of life [37, 42]. The mechanisms underlying these results are based on the activity of GLP-1 in controlling eating, acting on satiety signals [92] in areas of the brain involved in food intake regulation [93] and peripheral action, reducing gastric emptying and intestinal motility, and slowing absorption [94].

Therapeutic strategy and future perspectives of oral semaglutide

Given the prevalence of ASCVD in patients with diabetes [8], it is clear that GLP-1 analogues are underused. We currently have dulaglutide, liraglutide and sc semaglutide with approved CV indication (see Table 1). However, they are all in injectable form. Oral semaglutide benefits patients with high cardiovascular risk and is well accepted by patients [41]. Subjects from the PIONNEER 7 study showed comparable satisfaction between oral semaglutide and sitagliptin [41], a dipeptidyl peptidase-4 inhibitor (DPP-4i) largely used in monotherapy or combination when first-line treatment does not achieve adequate glycaemic control, but sitagliptin does not provide any cardiovascular benefit [95].

Oral presentation improves patients’ adherence, especially in chronic diseases. According to results from a multinational survey interviewing 3742 diabetic patients, an oral antidiabetic drug is preferable as the first choice of medication and medications for long-term use, especially for those with high HbA1c and comorbidities (obesity, hypertension, dyslipidaemia) [96]. Treatment satisfaction is directly related to adherence [97]. Patients from the PIONEER trials had higher satisfaction with oral semaglutide [38, 41, 42] than with placebo [38, 39, 42] and sitagliptin [41], especially in regard to hyperglycaemia. Moreover, preliminary data from real-world studies show a better metabolic control of T2DM patients with oral semaglutide, which is related to good treatment adherence [98, 99].

The best timing for introducing oral semaglutide has not yet been established. It is important to be more efficient in T2DM treatment starting from the time of diagnosis. In the Verify study, patients received a DPP4i, vildagliptin, along with metformin as an early treatment [100]. This early combination therapy with drugs targeting different actions provided better blood glucose control, decreased treatment failure, and extended the time to initiating insulin therapy [100]. It is expected that early combination therapy modifies the natural history of the disease. We could expect from early treatment with oral semaglutide and other GLP-1 analogues a better control of cardiovascular risks as a result of its actions exerted before atherosclerosis develops, in addition to the benefits of superior glucose control and weight loss.

Non-alcoholic steatohepatitis (NASH) is highly prevalent in T2DM patients, with high morbidity and mortality [101]. Compared to individuals without steatosis, patients with NASH have an increased incidence of ASCVD (HR 1.37, 95% CI 1.10–1.72) [102] and fatal and nonfatal MACEs (OR: 1.64, 95% CI 1.26–2.13) [103]. The physiopathology of NASH involves genes that increase plasma lipids and release procoagulant and proinflammatory factors, resulting in a higher risk for cardiovascular events [104]. Semaglutide benefits patients with NASH. In a preclinical study, sc semaglutide reduced hepatic TAGs and decreased the expression of 3 of 5 collagen genes and other inflammatory markers responsible for the development of liver fibrosis [50]. A phase 2 clinical study showed resolution of NASH and no worsening of fibrosis in 59% of patients treated with a higher dose of sc semaglutide compared with 17% of patients treated with placebo (p < 0.001) [105]. The oral presentation has not yet been studied for this indication, but encouraging evidence should be expected in the future. The impact of NASH treatment on ASCVD is still unknown.


The oral GLP-1 analogue semaglutide is a new drug that adds several benefits to diabetes treatment in addition to blood glucose control. It has the advantages of oral use, weight reduction, and potential positive cardiovascular effects in clinical practice. The antiatherogenic effect of the GLP-1 class is widely described in the literature, but we still need more clinical evidence on the cardiovascular impact in patients with diabetes. Data on the long-term efficacy of oral semaglutide for the significant reduction in MACEs are expected, as clinical studies are already being conducted. This medication is a safe option and should be part of clinicians’ arsenal to decrease cardiovascular risk in T2DM patients.

Availability of data and materials

Not applicable.



Atherosclerotic cardiovascular disease


Coronary heart disease


Confidence interval


Cardiovascular disease


Cardiovascular outcome trial


Dipeptidyl peptidase-4 inhibitor


Glucagon-like peptide 1


Glucagon-like peptide 1 receptor


Glycated haemoglobin


Hazard ratio


Low-density lipoprotein


Major cardiovascular events


Nitric oxide


Odds ratio


Peptide Innovation for Early Diabetes Treatment


Reactive oxygen species




Sodium N-[8-(2-hydroxybenzoyl)amino] caprylate






Type 2 diabetes mellitus


Very-low-density lipoprotein


  1. Litwak L, Goh SY, Hussein Z, Malek R, Prusty V, Khamseh ME. Prevalence of diabetes complications in people with type 2 diabetes mellitus and its association with baseline characteristics in the multinational A1chieve study. Diabetol Metab Syndr. 2013;5:57.

    Article  PubMed  PubMed Central  Google Scholar 

  2. GBD 2019 Risk Factors Collaborators. Global burden of 87 risk factors in 204 countries and territories, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet 2020;396:1223–49.

  3. International Diabetes Federation. IDF Diabetes Atlas— 9th Edition. Accessed 21 Dec 2020.

  4. Wilmot EG, Edwardson CL, Achana FA, Davies MJ, Gorely T, Gray LJ, et al. Sedentary time in adults and the association with diabetes, cardiovascular disease and death: systematic review and meta-analysis. Diabetologia. 2012;55:2895–905.

    Article  CAS  PubMed  Google Scholar 

  5. Schwingshackl L, Hoffmann G, Lampousi AM, Knüppel S, Iqbal K, Schwedhelm C, et al. Food groups and risk of type 2 diabetes mellitus: a systematic review and meta-analysis of prospective studies. Eur J Epidemiol. 2017;32:363–75.

    Article  PubMed  PubMed Central  Google Scholar 

  6. Abdullah A, Peeters A, de Courten M, Stoelwinder J. The magnitude of association between overweight and obesity and the risk of diabetes: a meta-analysis of prospective cohort studies. Diabetes Res Clin Pract. 2010;89:309–19.

    Article  PubMed  Google Scholar 

  7. Dendup T, Feng X, Clingan S, Astell-Burt T. Environmental risk factors for developing type 2 diabetes mellitus: a systematic review. Int J Environ Res Public Health. 2018;15:78.

    Article  PubMed Central  Google Scholar 

  8. Mosenzon O, Alguwaihes A, Arenas Leon JL, Bayram F, Darmon P, Davis T, et al. CAPTURE: a cross-sectional study of the contemporary (2019) prevalence of cardiovascular disease in adults with type 2 diabetes across 13 countries.!/9143/presentation/485. Accessed 8 May 2021.

  9. Vencio S, Vianna A, Silva M, Berbara T, Precoma D. CAPTURE: a cross-sectional study of the contemporary (2019) prevalence of cardiovascular disease in adults with type 2 diabetes in Brazil. Braz Arch Endocrinol Metabol. 2020;64:S38.

    Google Scholar 

  10. Preiss D, Sattar N, McMurray JJ. A systematic review of event rates in clinical trials in diabetes mellitus: the importance of quantifying baseline cardiovascular disease history and proteinuria and implications for clinical trial design. Am Heart J. 2011;161:210–1.

    Article  PubMed  Google Scholar 

  11. Williams SB, Cusco JA, Roddy MA, Johnstone MT, Creager MA. Impaired nitric oxide-mediated vasodilation in patients with non-insulin-dependent diabetes mellitus. J Am Coll Cardiol. 1996;27:567–74.

    Article  CAS  PubMed  Google Scholar 

  12. Gimbrone MA Jr, García-Cardeña G. Endothelial cell dysfunction and the pathobiology of atherosclerosis. Circ Res. 2016;118:620–36.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  13. Cardillo C, Campia U, Bryant MB, Panza JA. Increased activity of endogenous endothelin in patients with type II diabetes mellitus. Circulation. 2002;106:1783–7.

    Article  CAS  PubMed  Google Scholar 

  14. Erem C, Hacihasanoğlu A, Celik S, Ovali E, Ersöz HO, Ukinç K, et al. Coagulation and fibrinolysis parameters in type 2 diabetic patients with and without diabetic vascular complications. Med Princ Pract. 2005;14:22–30.

    Article  PubMed  Google Scholar 

  15. Nicholls SJ, Tuzcu EM, Kalidindi S, Wolski K, Moon KW, Sipahi I, et al. Effect of diabetes on progression of coronary atherosclerosis and arterial remodeling: a pooled analysis of 5 intravascular ultrasound trials. J Am Coll Cardiol. 2008;52:255–62.

    Article  CAS  PubMed  Google Scholar 

  16. Moreno PR, Murcia AM, Palacios IF, Leon MN, Bernardi VH, Fuster V, et al. Coronary composition and macrophage infiltration in atherectomy specimens from patients with diabetes mellitus. Circulation. 2000;102:2180–4.

    Article  CAS  PubMed  Google Scholar 

  17. Prattichizzo F, de Candia P, De Nigris V, Nicolucci A, Ceriello A. Legacy effect of intensive glucose control on major adverse cardiovascular outcome: systematic review and meta-analyses of trials according to different scenarios. Metabolism. 2020;110:154308.

    Article  CAS  PubMed  Google Scholar 

  18. Monami M, Genovese S, Mannucci E. Cardiovascular safety of sulfonylureas: a meta-analysis of randomized clinical trials. Diabetes Obes Metab. 2013;15:938–53.

    Article  CAS  PubMed  Google Scholar 

  19. Grenet G, Ribault S, Nguyen GB, Glais F, Metge A, Linet T, et al. GLUcose COntrol Safety & Efficacy in type 2 DIabetes, a systematic review and NETwork meta-analysis. PLoS ONE. 2019;14:e0217701.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  20. Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med. 2007;356:2457–71.

    Article  CAS  PubMed  Google Scholar 

  21. Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373:2117–28.

    Article  CAS  PubMed  Google Scholar 

  22. Marso SP, Daniels GH, Brown-Frandsen K, Kristensen P, Mann JF, Nauck MA, et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2016;375:311–22.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  23. Marathe CS, Rayner CK, Jones KL, Horowitz M. Glucagon-like peptides 1 and 2 in health and disease: a review. Peptides. 2013;44:75–86.

    Article  CAS  PubMed  Google Scholar 

  24. Latorre R, Sternini C, De Giorgio R, Greenwood-VanMeerveld B. Enteroendocrine cells: a review of their role in brain-gut communication. Neurogastroenterol Motil. 2016;28:620–30.

    Article  CAS  PubMed  Google Scholar 

  25. Alvarez E, Martinez MD, Roncero I, Chowen JA, Garcia-Cuartero B, Gispert JD, et al. The expression of GLP-1 receptor mRNA and protein allows the effect of GLP-1 on glucose metabolism in the human hypothalamus and brainstem. J Neurochem. 2005;92:798–806.

    Article  CAS  PubMed  Google Scholar 

  26. Pyke C, Heller RS, Kirk RK, Ørskov C, Reedtz-Runge S, Kaastrup P, et al. GLP-1 receptor localization in monkey and human tissue: novel distribution revealed with extensively validated monoclonal antibody. Endocrinology. 2014;155:1280–90.

    Article  PubMed  CAS  Google Scholar 

  27. Wei Y, Mojsov S. Tissue-specific expression of the human receptor for glucagon-like peptide-I: brain, heart and pancreatic forms have the same deduced amino acid sequences. FEBS Lett. 1995;358:219e24.

    Article  Google Scholar 

  28. Green BD, Hand KV, Dougan JE, McDonnell BM, Cassidy RS, Grieve DJ. GLP-1 and related peptides cause concentration-dependent relaxation of rat aorta through a pathway involving KATP and cAMP. Arch Biochem Biophys. 2008;478:136e42.

    Article  CAS  Google Scholar 

  29. Nyström T, Gutniak MK, Zhang Q, Zhang F, Holst JJ, Ahrén B, et al. Effects of glucagon-like peptide-1 on endothelial function in type 2 diabetes patients with stable coronary artery disease. Am J Physiol Endocrinol Metab. 2004;287(6):E1209–15.

    Article  PubMed  CAS  Google Scholar 

  30. Hare KJ, Knop FK, Asmar M, Madsbad S, Deacon CF, Holst JJ, et al. Preserved inhibitory potency of GLP-1 on glucagon secretion in type 2 diabetes mellitus. J Clin Endocrinol Metab. 2009;94:4679–87.

    Article  CAS  PubMed  Google Scholar 

  31. Philippart M, Schmidt J, Bittner B. Oral delivery of therapeutic proteins and peptides: an overview of current technologies and recommendations for bridging from approved intravenous or subcutaneous administration to novel oral regimens. Drug Res (Stuttg). 2016;66:113–20.

    CAS  Google Scholar 

  32. Di L. Strategic approaches to optimizing peptide ADME properties. AAPS J. 2015;17:134–43.

    Article  CAS  PubMed  Google Scholar 

  33. Buckley ST, Bækdal TA, Vegge A, Maarbjerg SJ, Pyke C, Ahnfelt-Rønne J, et al. Transcellular stomach absorption of a derivatized glucagon-like peptide-1 receptor agonist. Sci Transl Med. 2018;10:eaar7047.

    Article  PubMed  CAS  Google Scholar 

  34. Drucker DJ. Advances in oral peptide therapeutics. Nat Rev Drug Discov. 2020;19:277–89.

    Article  CAS  PubMed  Google Scholar 

  35. Aroda VR, Rosenstock J, Terauchi Y, Altuntas Y, Lalic NM, Morales Villegas EC, et al. PIONEER 1: randomized clinical trial of the efficacy and safety of oral semaglutide monotherapy in comparison with placebo in patients with type 2 diabetes. Diabetes Care. 2019;42(9):1724–32.

    Article  CAS  PubMed  Google Scholar 

  36. Rodbard HW, Rosenstock J, Canani LH, Deerochanawong C, Gumprecht J, Lindberg SØ, et al. Oral semaglutide versus empagliflozin in patients with type 2 diabetes uncontrolled on metformin: the PIONEER 2 Trial. Diabetes Care. 2019;42:2272–81.

    Article  CAS  PubMed  Google Scholar 

  37. Rosenstock J, Allison D, Birkenfeld AL, Blicher TM, Deenadayalan S, Jacobsen JB, et al. Effect of additional oral semaglutide vs sitagliptin on glycated hemoglobin in adults with type 2 diabetes uncontrolled with metformin alone or with sulfonylurea: the PIONEER 3 randomized clinical trial. JAMA. 2019;321:1466–80.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  38. Pratley R, Amod A, Hoff ST, Kadowaki T, Lingvay I, Nauck M, et al. Oral semaglutide versus subcutaneous liraglutide and placebo in type 2 diabetes (PIONEER 4): a randomised, double-blind, phase 3a trial. Lancet. 2019;394:39–50.

    Article  CAS  PubMed  Google Scholar 

  39. Mosenzon O, Blicher TM, Rosenlund S, Eriksson JW, Heller S, Hels OH, et al. Efficacy and safety of oral semaglutide in patients with type 2 diabetes and moderate renal impairment (PIONEER 5): a placebo-controlled, randomised, phase 3a trial. Lancet Diabetes Endocrinol. 2019;7:515–27.

    Article  CAS  PubMed  Google Scholar 

  40. Husain M, Birkenfeld AL, Donsmark M, Dungan K, Eliaschewitz FG, Franco DR, et al. Oral semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2019;381:841–51.

    Article  CAS  PubMed  Google Scholar 

  41. Pieber TR, Bode B, Mertens A, Cho YM, Christiansen E, Hertz CL, et al. Efficacy and safety of oral semaglutide with flexible dose adjustment versus sitagliptin in type 2 diabetes (PIONEER 7): a multicentre, open-label, randomised, phase 3a trial. Lancet Diabetes Endocrinol. 2019;7:528–39.

    Article  CAS  PubMed  Google Scholar 

  42. Zinman B, Aroda VR, Buse JB, Cariou B, Harris SB, Hoff ST, et al. Efficacy, safety, and tolerability of oral semaglutide versus placebo added to insulin with or without metformin in patients with type 2 diabetes: the PIONEER 8 trial. Diabetes Care. 2019;42:2262–71.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  43. Bethel MA, Patel RA, Merrill P, Lokhnygina Y, Buse JB, Mentz RJ, et al. Cardiovascular outcomes with glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes: a meta-analysis. Lancet Diabetes Endocrinol. 2018;6:105–13.

    Article  PubMed  Google Scholar 

  44. Cosentino F, Grant PJ, Aboyans V, Bailey CJ, Ceriello A, Delgado V, et al. ESC Scientific Document Group 2019. ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. Eur Heart J. 2020;41:255–323.

    Article  PubMed  Google Scholar 

  45. American Diabetes Association. Cardiovascular Disease and Risk Management: Standards of Medical Care in Diabetes—2021. Diabetes Care. 2021;44(Suppl 1):125–50.

    Article  Google Scholar 

  46. Dzau VJ, Antman EM, Black HR, Hayes DL, Manson JE, Plutzky J, et al. The cardiovascular disease continuum validated: clinical evidence of improved patient outcomes: part I: pathophysiology and clinical trial evidence (risk factors through stable coronary artery disease). Circulation. 2006;114:2850–70.

    Article  PubMed  Google Scholar 

  47. Holst JJ, Deacon CF, Vilsbøll T, Krarup T, Madsbad S. Glucagon-like peptide-1, glucose homeostasis and diabetes. Trends Mol Med. 2008;14:161–8.

    Article  CAS  PubMed  Google Scholar 

  48. Farr S, Taher J, Adeli K. Glucagon-like peptide-1 as a key regulator of lipid and lipoprotein metabolism in fasting and postprandial states. Cardiovasc Hematol Disord Drug Targets. 2014;14:126–36.

    Article  CAS  PubMed  Google Scholar 

  49. Yamamoto H, Lee CE, Marcus JN, Williams TD, Overton JM, Lopez ME, et al. Glucagon-like peptide-1 receptor stimulation increases blood pressure and heart rate and activates autonomic regulatory neurons. J Clin Invest. 2002;110:43–52.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  50. Rakipovski G, Rolin B, Nøhr J, Klewe I, Frederiksen KS, Augustin R, et al. The GLP-1 analogs liraglutide and semaglutide reduce atherosclerosis in ApoE/ and LDLr/ mice by a mechanism that includes inflammatory pathways. JACC Basic Transl Sci. 2018;3:844–57.

    Article  PubMed  PubMed Central  Google Scholar 

  51. Drucker DJ. The cardiovascular biology of glucagon-like peptide-1. Cell Metab. 2016;24:15–30.

    Article  CAS  PubMed  Google Scholar 

  52. Basu A, Charkoudian N, Schrage W, Rizza RA, Basu R, Joyner MJ. Beneficial effects of GLP-1 on endothelial function in humans: dampening by glyburide but not by glimepiride. Am J Physiol Endocrinol Metab. 2007;293:E1289–95.

    Article  CAS  PubMed  Google Scholar 

  53. Noyan-Ashraf MH, Momen MA, Ban K, Sadi AM, Zhou YQ, Riazi AM, et al. GLP-1R agonist liraglutide activates cytoprotective pathways and improves outcomes after experimental myocardial infarction in mice. Diabetes. 2009;58:975–83.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  54. Hernandez AF, Green JB, Janmohamed S, D’Agostino RB Sr, Granger CB, Jones NP, et al. Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial. Lancet. 2018;392:1519–29.

    Article  CAS  PubMed  Google Scholar 

  55. A heart disease study of semaglutide in patients with type 2 diabetes (SOUL). identifier: NCT03914326. Accessed 28 Dec 2020.

  56. Tsapas A, Avgerinos I, Karagiannis T, Malandris K, Manolopoulos A, Andreadis P, et al. Comparative effectiveness of glucose-lowering drugs for type 2 diabetes: a systematic review and network meta-analysis. Ann Intern Med. 2020;173:278–86.

    Article  PubMed  Google Scholar 

  57. Marso SP, Bain SC, Consoli A, Eliaschewitz FG, Jódar E, Leiter LA, et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2016;375:1834–44.

    Article  CAS  PubMed  Google Scholar 

  58. Overgaard RV, Navarria A, Hertz CL, Ingwersen SH. Similar efficacy and gastrointestinal tolerability versus exposure for oral and subcutaneous semaglutide. Diabetologia. 2019;62:S375.

    Google Scholar 

  59. Nuhoho S, Gupta J, Hansen BB, Fletcher-Louis M, Dang-Tan T, Paine A. Orally administered semaglutide versus GLP-1 RAs in patients with type 2 diabetes previously receiving 1–2 oral antidiabetics: systematic review and network meta-analysis. Diabetes Ther. 2019;10(6):2183–99.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  60. Davies M, Pieber TR, Hartoft-Nielsen ML, Hansen OKH, Jabbour S, Rosenstock J. Effect of oral semaglutide compared with placebo and subcutaneous semaglutide on glycemic control in patients with type 2 diabetes: a randomized clinical trial. JAMA. 2017;318:1460–70.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  61. Husain M, Bain SC, Holst AG, Mark T, Rasmussen S, Lingvay I. Effects of semaglutide on risk of cardiovascular events across a continuum of cardiovascular risk: combined post hoc analysis of the SUSTAIN and PIONEER trials. Cardiovasc Diabetol. 2020;19(1):156.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  62. Husain M, Bain SC, Jeppesen OK, Lingvay I, Sørrig R, Treppendahl MB, et al. Semaglutide (SUSTAIN and PIONEER) reduces cardiovascular events in type 2 diabetes across varying cardiovascular risk. Diabetes Obes Metab. 2020;22:442–51.

    Article  PubMed  PubMed Central  Google Scholar 

  63. GBD 2016 Stroke Collaborators. Global, regional, and national burden of stroke, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol. 2019;18:439–58.

  64. Lau LH, Lew J, Borschmann K, Thijs V, Ekinci EI. Prevalence of diabetes and its effects on stroke outcomes: a meta-analysis and literature review. J Diabetes Investig. 2019;10:780–92.

    Article  PubMed  Google Scholar 

  65. Ballard C, Nørgaard CH, Friedrich S, Mørch LS, Gerds T, Moller DV, et al. Liraglutide and semaglutide: pooled post-hoc analysis to evaluate risk of dementia in patients with type 2 diabetes. Alzheimer’s Dement. 2020;16(Suppl 9):e042909.

    Google Scholar 

  66. Yang X, Feng P, Zhang X, Li D, Wang R, Ji C, et al. The diabetes drug semaglutide reduces infarct size, inflammation, and apoptosis, and normalizes neurogenesis in a rat model of stroke. Neuropharmacology. 2019;158:107748.

    Article  CAS  PubMed  Google Scholar 

  67. Erbil D, Eren CY, Demirel C, Küçüker MU, Solaroğlu I, Eser HY. GLP-1’s role in neuroprotection: a systematic review. Brain Inj. 2019;33:734–819.

    Article  PubMed  Google Scholar 

  68. Duan XY, Liu SY, Yin DG. Comparative efficacy of 5 sodium glucose cotransporter 2 inhibitor and 7 glucagon-like peptide 1 receptor agonists interventions on cardiorenal outcomes in type 2 diabetes patients: a network meta-analysis based on cardiovascular or renal outcome trials. Medicine (Baltimore). 2021;100(30):e26431.

    Article  CAS  Google Scholar 

  69. Rowlands J, Heng J, Newsholme P, Carlessi R. Pleiotropic effects of GLP-1 and analogs on cell signaling, metabolism, and function. Front Endocrinol (Lausanne). 2018;9:672.

    Article  Google Scholar 

  70. Cai X, She M, Xu M, Chen H, Li J, Chen X, et al. GLP-1 treatment protects endothelial cells from oxidative stress-induced autophagy and endothelial dysfunction. Int J Biol Sci. 2018;14:1696–708.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  71. Siraj MA, Mundil D, Beca S, Momen A, Shikatani EA, Afroze T, et al. Cardioprotective GLP-1 metabolite prevents ischemic cardiac injury by inhibiting mitochondrial trifunctional protein-α. J Clin Invest. 2020;130:1392–404.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  72. Nikolaidis LA, Mankad S, Sokos GG, Miske G, Shah A, Elahi D, et al. Effects of glucagon-like peptide-1 in patients with acute myocardial infarction and left ventricular dysfunction after successful reperfusion. Circulation. 2004;109:962-s65.

    Article  CAS  PubMed  Google Scholar 

  73. Nagashima M, Watanabe T, Terasaki M, Tomoyasu M, Nohtomi K, Kim-Kaneyama J, et al. Native incretins prevent the development of atherosclerotic lesions in apolipoprotein E knockout mice. Diabetologia. 2011;54:2649–59.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  74. Després JP. Body fat distribution and risk of cardiovascular disease: an update. Circulation. 2012;126:1301–13.

    Article  PubMed  Google Scholar 

  75. Lacobellis G, Villasante Fricke AC. Effects of semaglutide versus dulaglutide on epicardial fat thickness in subjects with type 2 diabetes and obesity. J Endocr Soc. 2020;4:bvz042.

    Article  CAS  Google Scholar 

  76. Meier JJ, Gethmann A, Gotze O, Gallwitz B, Holst JJ, Schmidt WE, et al. Glucagon-like peptide 1 abolishes the postprandial rise in triglyceride concentrations and lowers levels of non-esterified fatty acids in humans. Diabetologia. 2006;49:452–8.

    Article  CAS  PubMed  Google Scholar 

  77. Vergès B, Duvillard L, Pais de Barros JP, Bouillet B, Baillot-Rudoni S, Rouland A, et al. Liraglutide reduces postprandial hyperlipidemia by increasing ApoB48 (Apolipoprotein B48) catabolism and by reducing ApoB48 production in patients with type 2 diabetes mellitus. Arterioscler Thromb Vasc Biol. 2018;38:2198–206.

    Article  PubMed  CAS  Google Scholar 

  78. Vergès B, Duvillard L, Pais de Barros JP, Bouillet B, Baillot-Rudoni S, Rouland A, et al. Liraglutide increases the catabolism of apolipoprotein B100-containing lipoproteins in patients with type 2 diabetes and reduces proprotein convertase subtilisin/kexin type 9 expression. Diabetes Care. 2021;44:1027–37.

    Article  PubMed  CAS  Google Scholar 

  79. Yue W, Li Y, Ou D, Yang Q. The GLP-1 receptor agonist liraglutide protects against oxidized LDL-induced endothelial inflammation and dysfunction via KLF2. IUBMB Life. 2019;71:1347–54.

    Article  CAS  PubMed  Google Scholar 

  80. Zweck E, Westenfeld R, Szendroedi J. Oral semaglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2019;381:2075–6.

    Article  PubMed  Google Scholar 

  81. Ryan DH, Lingvay I, Colhoun HM, Deanfield J, Emerson SS, Kahn SE, et al. Semaglutide effects on cardiovascular outcomes in people with overweight or obesity (SELECT) rationale and design. Am Heart J. 2020;229:61–9.

    Article  PubMed  Google Scholar 

  82. Warren M, Chaykin L, Trachtenbarg D, Nayak G, Wijayasinghe N, Cariou B. Semaglutide as a therapeutic option for elderly patients with type 2 diabetes: Pooled analysis of the SUSTAIN 1–5 trials. Diabetes Obes Metab. 2018;20:2291–7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  83. World Health Organization. Obesity and Overweight Fact Sheet. Assessed 8 May 2021.

  84. Wilson PW, D’Agostino RB, Sullivan L, Parise H, Kannel WB. Overweight and obesity as determinants of cardiovascular risk: the framingham experience. Arch Intern Med. 2002;162:1867–72.

    Article  PubMed  Google Scholar 

  85. Bastard JP, Maachi M, Lagathu C, Kim MJ, Caron M, Vidal H, et al. Recent advances in the relationship between obesity, inflammation, and insulin resistance. Eur Cytokine Netw. 2006;17:4–12.

    CAS  PubMed  Google Scholar 

  86. Lee SY, Chang HJ, Sung J, Kim KJ, Shin S, Cho IJ, et al. The impact of obesity on subclinical coronary atherosclerosis according to the risk of cardiovascular disease. Obesity (Silver Spring). 2014;22:1762–8.

    Article  Google Scholar 

  87. Lean ME, Leslie WS, Barnes AC, Brosnahan N, Thom G, McCombie L, et al. Primary care-led weight management for remission of type 2 diabetes (DiRECT): an open-label, cluster-randomised trial. Lancet. 2018;391:541–51.

    Article  PubMed  Google Scholar 

  88. The Look AHEAD Research Group. Cardiovascular effects of intensive lifestyle intervention in type 2 diabetes. N Engl J Med. 2013;369:145–54.

    Article  PubMed Central  CAS  Google Scholar 

  89. Look AHEAD Research Group, Gregg EW, Jakicic JM, Blackburn G, Bloomquist P, Bray GA, et al. Association of the magnitude of weight loss and changes in physical fitness with long-term cardiovascular disease outcomes in overweight or obese people with type 2 diabetes: a post-hoc analysis of the Look AHEAD randomised clinical trial. Lancet Diabetes Endocrinol. 2016;4:913–21.

  90. Ghosh-Swaby OR, Goodman SG, Leiter LA, Cheng A, Connelly KA, Fitchett D, et al. Glucose-lowering drugs or strategies, atherosclerotic cardiovascular events, and heart failure in people with or at risk of type 2 diabetes: an updated systematic review and meta-analysis of randomised cardiovascular outcome trials. Lancet Diabetes Endocrinol. 2020;8:418–35.

    Article  CAS  PubMed  Google Scholar 

  91. Casanueva FF, Moreno B, Rodriguez-Azeredo R, Massien C, Conthe P, Formiguera X, et al. Relationship of abdominal obesity with cardiovascular disease, diabetes and hyperlipidaemia in Spain. Clin Endocrinol. 2010;73:35–40.

    Google Scholar 

  92. Williams DL, Baskin DG, Schwartz MW. Evidence that intestinal glucagonlike peptide-1 plays a physiological role in satiety. Endocrinology. 2009;150:1680–7.

    Article  CAS  PubMed  Google Scholar 

  93. Chaudhri OB, Parkinson JR, Kuo YT, Druce MR, Herlihy AH, Bell JD, et al. Differential hypothalamic neuronal activation following peripheral injection of GLP-1 and oxyntomodulin in mice detected by manganese enhanced magnetic resonance imaging. Biochem Biophys Res Commun. 2006;350:298–306.

    Article  CAS  PubMed  Google Scholar 

  94. Nakatani Y, Maeda M, Matsumura M, Shimizu R, Banba N, Aso Y, et al. Effect of GLP-1 receptor agonist on gastrointestinal tract motility and residue rates as evaluated by capsule endoscopy. Diabetes Metab. 2017;43:430–7.

    Article  CAS  PubMed  Google Scholar 

  95. Wu S, Hopper I, Skiba M, Krum H. Dipeptidyl peptidase-4 inhibitors and cardiovascular outcomes: meta-analysis of randomized clinical trials with 55,141 participants. Cardiovasc Ther. 2014;32:147–58.

    Article  CAS  PubMed  Google Scholar 

  96. Dibonaventura MD, Wagner JS, Girman CJ, Brodovicz K, Zhang Q, Qiu Y, et al. Multinational internet-based survey of patient preference for newer oral or injectable type 2 diabetes medication. Patient Prefer Adherence. 2010;4:397–406.

    Article  PubMed  PubMed Central  Google Scholar 

  97. Saisho Y. Use of diabetes treatment satisfaction questionnaire in diabetes care: importance of patient-reported outcomes. Int J Environ Res Public Health. 2018;15:947.

    Article  PubMed Central  Google Scholar 

  98. Shivappa N, Swift C, Noone J, Du S, Radin M, Gamble C. 86-LB: Real-world effectiveness of oral semaglutide (OS) from a U.S. commercially insured and medicare advantage population. Diabetes. 2021; 70(Supplement 1).

  99. Aroda VR, Faurby M, Lophaven S, Noone J, Wolden ML, Lingvay I. Insights into the early use of oral semaglutide in routine clinical practice: the IGNITE study. Diabetes Obes Metab. 2021;23(9):2177–82.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  100. Matthews DR, Paldánius PM, Proot P, Chiang Y, Stumvoll M, Del Prato S, VERIFY study group. Glycaemic durability of an early combination therapy with vildagliptin and metformin versus sequential metformin monotherapy in newly diagnosed type 2 diabetes (VERIFY): a 5-year, multicentre, randomised, double-blind trial. Lancet. 2019;394:1519–29.

    Article  CAS  PubMed  Google Scholar 

  101. Younossi ZM, Golabi P, de Avila L, Paik JM, Srishord M, Fukui N, et al. The global epidemiology of NAFLD and NASH in patients with type 2 diabetes: a systematic review and meta-analysis. J Hepatol. 2019;71:793–801.

    Article  PubMed  Google Scholar 

  102. Wu S, Wu F, Ding Y, Hou J, Bi J, Zhang Z. Association of non-alcoholic fatty liver disease with major adverse cardiovascular events: a systematic review and meta-analysis. Sci Rep. 2016;6:33386.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  103. Targher G, Byrne CD, Lonardo A, Zoppini G, Barbui C. Non-alcoholic fatty liver disease and risk of incident cardiovascular disease: a meta-analysis. J Hepatol. 2016;65:589–600.

    Article  PubMed  Google Scholar 

  104. Stols-Gonçalves D, Hovingh GK, Nieuwdorp M, Holleboom AG. NAFLD and atherosclerosis: two sides of the same dysmetabolic coin? Trends Endocrinol Metab. 2019;30:891–902.

    Article  PubMed  CAS  Google Scholar 

  105. Newsome PN, Buchholtz K, Cusi K, Linder M, Okanoue T, Ratziu V, et al. A placebo-controlled trial of subcutaneous semaglutide in nonalcoholic steatohepatitis. N Engl J Med. 2021;384:1113–24.

    Article  CAS  PubMed  Google Scholar 

  106. Pfeffer MA, Claggett B, Diaz R, Dickstein K, Gerstein HC, Køber LV, et al. Lixisenatide in patients with type 2 diabetes and acute coronary syndrome. N Engl J Med. 2015;373(23):2247–57.

    Article  CAS  PubMed  Google Scholar 

  107. Holman RR, Bethel MA, Mentz RJ, Thompson VP, Lokhnygina Y, Buse JB, et al. Effects of once-weekly exenatide on cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2017;377:1228–39.

    Article  CAS  PubMed  Google Scholar 

  108. Gerstein HC, Colhoun HM, Dagenais GR, Diaz R, Lakshmanan M, Pais P, et al. Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial. Lancet. 2019;394:121–30.

    Article  CAS  PubMed  Google Scholar 

Download references


Dr. Mariana Matos, MD provided medical writing support on behalf of Springer Healthcare in accordance with Good Publication Practice (GPP3) guidelines.


This work was supported by Novo Nordisk Farmacêutica do Brasil LTDA. Authors' contributions: JS and DF participated in the conception and design of the review, revised the whole manuscript, and read and approved the final manuscript.

Author information

Authors and Affiliations



All authors read and approved the final manuscript.

Corresponding author

Correspondence to Denise Franco.

Ethics declarations

Ethics approval and consent to participate

Not applicable.

Consent for publication

Not applicable.

Competing interests

Dr. José Francisco Kerr Saraiva is the national leader of the SOUL and SELECT trials. He is part of the Novo Nordisk Global Expert Panel. He receives fees to give lectures by Novo Nordisk, Lilly, Novartis, Boehringer Ingelheim, Merck, and Sharp & Dohme. Dr. Denise Franco is the principal investigator in cardiovascular risk studies of oral and injectable semaglutide. She is part of the Novo Nordisk, Medtronic, Sanofi, Abbott, and Biomm advisory boards. She receives fees to give lectures by Novo Nordisk, Lilly, Novartis, AstraZeneca, Medtronic, Biomm, Sanofi, Abbott, and Roche.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary Information

Additional file 1:

Table S1. Cardiovascular events reported during the PIONEER program with oral semaglutide.

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit The Creative Commons Public Domain Dedication waiver ( applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Saraiva, J.F.K., Franco, D. Oral GLP-1 analogue: perspectives and impact on atherosclerosis in type 2 diabetic patients. Cardiovasc Diabetol 20, 235 (2021).

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: